Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 10;39(2):155-169.
doi: 10.1200/JCO.20.02953. Epub 2020 Dec 8.

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care

Affiliations

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care

Nathan A Pennell et al. J Clin Oncol. .

Abstract

This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.20.02953.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I 5 Immediate Family Member, Inst 5 My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Nathan A. Pennell

Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare,Merck, Bristol-Myers Squibb, Inivata, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera

Research Funding: Celgene, AstraZeneca, Pfizer, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL

Melissa Dillmon

Stock and Other Ownership Interests: Johnson & Johnson

Consulting or Advisory Role: Puma Biotechnology

Ajjai S. Alva

Consulting or Advisory Role: AstraZeneca, Merck, Pfizer, Bristol-Myers Squibb

Research Funding: Genentech, Bristol-Myers Squibb, Merck Sharp & Dohme, Prometheus Laboratories, Mirati Therapeutics, AstraZeneca, Roche, Bayer, Progenics, Astellas Pharma, Arcus Biosciences, Harpoon Therapeutics, Celgene, Janssen

Travel, Accommodations, Expenses: Merck, Bristol-Myers Squibb

Sibel Blau

Employment: University of Washington, Northwest Medical Specialties

Leadership: Northwest Medical Specialties, QCCA Network, LLC

Stock and Other Ownership Interests: Northwest Medical Specialties

Honoraria: Adaptive Health Focus Group—Cardinal, Novartis Ribo Advisory Board, Puma Biotechnology, AJMC Institute of Value Based Oncology

Research Funding: Northwest Medical Specialties

Expert Testimony: Northwest Medical Specialties

Travel, Accommodations, Expenses: Northwest Medical Specialties

Other Relationship: Northwest Medical Specialties, All4Cure, Quality Cancer Care Alliance

Timothy L. Cannon

Consulting or Advisory Role: Loxo, Navican

Other Relationship: Navican/Intermountain Healthcare

Natalie R. Dickson

Employment: Tennessee Oncology, PLLC

Consulting or Advisory Role: Via Oncology, Synergy Healthcare, LLC, AbbVie

Research Funding: Bristol-Myers Squibb

Travel, Accommodations, Expenses: Flatiron Health

Maximilian Diehn

Stock and Other Ownership Interests: CiberMed, Foresight Diagnostics

Consulting or Advisory Role: Roche, AstraZeneca, Illumina, Reflexion Medical, Gritstone Oncology, BioNTech AG, Novartis

Research Funding: Varian Medical Systems, Illumina

Patents, Royalties, Other Intellectual Property: Patent filings on ctDNA detection assigned to Stanford University, Patent filings on tumor treatment resistance mechanisms assigned to Stanford University

Travel, Accommodations, Expenses: Roche, Varian Medical Systems, AstraZeneca

Tari King

Honoraria: Genomic Health

Consulting or Advisory Role: Genomic Health

Travel, Accommodations, Expenses: Oncoclinicas

Stacie C. Lindsey

Leadership: Cholangiocarcinoma Foundation

Travel, Accommodations, Expenses: Incyte

Jonathan Marron

Consulting or Advisory Role: Partner Therapeutics

Barbara L. McAneny

Employment: New Mexico Cancer Center, Innovative Oncology Business Solutions, American Medical Association

Leadership: AMA, New Mexico Cancer Center, Innovative Oncology Business Solutions

Stock and Other Ownership Interests: New Mexico Cancer Center, Innovative Oncology Business Solutions

Patents, Royalties, Other Intellectual Property: Innovative Oncology Business Solutions

Travel, Accommodations, Expenses: ASCO, COA, New Mexico Cancer Center, Innovative Oncology Business Solutions, American Medical Association

Other Relationship: National Cancer Care Alliance, American Medical Association

Kathryn Finch Mileham

Honoraria: Takeda

Consulting or Advisory Role: AstraZeneca, Bayer

Speakers’ Bureau: Merck

Research Funding: Celgene

Grzegorz S. Nowakowski

Consulting or Advisory Role: Celgene, MorphoSys, Genentech, Selvita, Debiopharm, Kite/Gilead

Research Funding: Celgene, NanoString Technologies, MorphoSys

Manali I. Patel

Consulting or Advisory Role: Celgene

Debra A. Patt

Employment: Texas Oncology, McKesson, MedNax, McKesson

Leadership: Mednax, Texas Oncology

Stock and Other Ownership Interests: Mednax

Consulting or Advisory Role: Pfizer, Roche, AstraZeneca

Research Funding: Merck, Eisai, Seattle Genetics, Lilly

Travel, Accommodations, Expenses: McKesson

Gladys Rodriguez

Stock and Other Ownership Interests: Novartis, Abbott Laboratories, Merck

Speakers’ Bureau: Genentech

Research Funding: Puma Biotechnology

Barry Russo

Employment: The Center for Cancer and Blood Disorders

Consulting or Advisory Role: Cardinal Health

Travel, Accommodations, Expenses: Cardinal Health

Cardinale B. Smith

Honoraria: Teva

Consulting or Advisory Role: Teva

Speakers’ Bureau: Teva

Eleonora Teplinsky

Honoraria: The France Foundation, InCrowd

Consulting or Advisory Role: GlaxoSmithKline

Travel, Accommodations, Expenses: The France Foundation

Tiffany A. Traina

Consulting or Advisory Role: Genentech/Roche, Pfizer, AstraZeneca, Merck, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol-Myers Squibb, Athenex, Aduro Biotech, Halozyme, Daiichi Sankyo, ION Pharma, Seattle Genetics, Eisai, Immunomedics

Speakers’ Bureau: Roche/Genentech, Eisai

Research Funding: Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma, Immunomedics, Genentech/Roche, Daiichi Sankyo, Carrick Pharm

Robin Zon

Stock and Other Ownership Interests: AC3—a Healthcare Technology Company, Cytosorbents, Moderna Therapeutics, Oncolytics, TG Therapeutics, Select Sector SPDR Health Care

Consulting or Advisory Role: New Century Health, Xentigen

Richard L. Schilsky

Research Funding: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech/Roche, Lilly, Merck, Pfizer, Boehringer Ingelheim

Travel, Accommodations, Expenses: Varian Medical Systems

Howard A. Burris

Employment: HCA Healthcare/Sarah Cannon

Leadership: HCA Healthcare/Sarah Cannon

Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon

Consulting or Advisory Role: AstraZeneca, FORMA Therapeutics, Celgene, Incyte

Research Funding: Roche/Genentech, Bristol-Myers Squibb, Incyte, AstraZeneca, MedImmune, Macrogenics, Novartis, Boehringer Ingelheim, Lilly, Seattle Genetics, Merck, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX Therapeutics, GlaxoSmithKline, Verastem, Tesaro, BioMed Valley Discoveries, TG Therapeutics, Vertex, eFFECTOR Therapeutics, Janssen, Gilead Sciences, BioAtla, CicloMed, Harpoon therapeutics, Arch, Arvinas, Revolution Medicines, Array BioPharma, Bayer, BIND Therapeutics, Kyocera, miRNA Therapeutics, Pfizer, Takeda/Millennium, Foundation Medicine

Expert Testimony: Novartis

Uncompensated Relationships: Daiichi Sankyo, Pfizer

No other potential conflicts of interest were reported.

References

    1. Waterhouse DM, Harvey RD, Hurley P, et al. : Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: Findings from an American Society of Clinical Oncology Survey. JCO Oncol Pract 16:417–421, 2020 - PubMed
    1. Tan AC, Ashley DM, Khasraw M: Adapting to a pandemic—Conducting oncology trials during the SARS-CoV-2 pandemic. Clin Cancer Res 1364:3100–3103, 2020 - PMC - PubMed
    1. Unger JM, Blanke CD, LeBlanc M, et al. : Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Network Open 3:e2010651, 2020 - PMC - PubMed
    1. Moskowitz CS, Panageas KS: Implications for design and analyses of oncology clinical trials during the COVID-19 pandemic. JAMA Oncol 6:1326–1327, 2020 - PubMed
    1. Fleming TR, Labriola D, Wittes J: Conducting clinical research during the COVID-19 pandemic: Protecting scientific integrity. JAMA 324:33–34, 2020 - PubMed

LinkOut - more resources